Market Whales and Their Recent Bets on CRSP Options
In terms of liquidity and interest, the mean open interest for CRISPR Therapeutics options trades today is 628.14 with a total volume of 1,152.00.
CRISPR Therapeutics AG (CRSP): Among the Most Oversold Healthcare Stocks to Buy Now
We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...
Harvard Medical School11h
Creating the World’s First CRISPR Medicine, for Sickle Cell Disease
In December 2023, through the development efforts of CRISPR Therapeutics and Vertex Pharmaceuticals, their decades-long ...
cweb1d
CRISPR Therapeutics AG (NASDAQ:CRSP) Overview: A Leader in Gene Editing
The consensus price target for CRISPR Therapeutics AG (NASDAQ:CRSP) has been adjusted from $72.75 to $65, reflecting changes in financial performance and industry developments. Despite a quarterly ...
CRSP Stock Rises 25% in a Week: Time to Buy, Hold or Sell?
The rise in CRISPR Therapeutics' share price can be attributed to the better-than-expected Q4 results and a rating upgrade by a well-established financial services firm.
Pharm Exec3d
2025 Pipeline Report: The Edge of Greatness?
Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...
Bahrain conducts 1st CRISPR-based sickle cell treatment outside U.S.
Bahrain has achieved a medical milestone by successfully treating a patient with sickle cell disease (SCD) using ...
Bahrain Oncology Center: Bahrain Makes History with First Successful CRISPR-Based Sickle Cell Treatment Outside the US
The Bahrain Oncology Centre (BOC) has made medical history by successfully treating a sickle cell disease (SCD) patient using ...
Bahrain Makes History with First Successful CRISPR-Based Sickle Cell Treatment Outside the US
The Bahrain Oncology Centre (BOC) has made medical history by successfully treating a sickle cell disease (SCD) patient using ...